ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation

Key Takeaways AngioDynamics expanded EU NanoKnife use to liver, pancreas, kidney and prostate tumors.ANGO will launch the LIVER-IRE Global Registry to assess real-world liver tumor outcomes.Europe drives 28% of global IRE volumes, supporting NanoKnife's multi-organ growth strategy.AngioDynamics (ANGO) recently announced expanded indications in Europe for its NanoKnife System, broadening its clinical utility in soft tissue tumor ablation. The expanded approval covers NanoKnife’s use for soft tissue ablation ...